GRI Bio is a clinical-stage biopharmaceutical company primarily focused on the development and commercialization of biopharmaceutical products. Co. is developing medications for central nervous system disorders with a focus on abuse-deterrent medications. Co.'s primary investigational product candidate, ADAIR, is a proprietary, abuse-deterrent oral formulation of immediate-release dextroamphetamine (the main active ingredient in Adderall®) for the treatment of attention-deficit/hyperactivity disorder and narcolepsy. ADAIR is designed to deter attempts to crush and snort and to provide barriers to injection while still providing the therapeutic benefit when taken orally. We show 2 historical shares outstanding datapoints in our GRI shares outstanding history coverage, used to compute GRI market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing GRI market cap history over the course of time is important for investors
interested in comparing GRI's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of GRI versus a peer is one thing; comparing
GRI market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like GRI can fluctuate over the course of history.
With this page we aim to empower investors researching GRI by allowing them to research the GRI market cap history. |
Free GRI Email Alerts:
Video: The Importance of Market Cap
